Pfizer And Sangamo Start Phase III Study For Hemophilia A Gene Therapy
Giroctocogene Fitelparvovec Sustains Factor VIII Levels With No Bleeds
The move into Phase III for giroctocogene fitelparvovec comes on the heels of BioMarin's surprise setback when the FDA demanded more proof of durability of its rival hemophilia A gene therapy Roctavian.
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.